108 related articles for article (PubMed ID: 27506103)
1. [THE EVOLUTION OF MARKERS OF PROSTATE CANCER].
Peshkov MN; Generozov EV; Kostryukova ES
Klin Lab Diagn; 2016 Mar; 61(3):132-40. PubMed ID: 27506103
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
5. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
6. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
7. [Genome-wide analysis of DNA methylation in prostate cancer using the technology of Infinium HumanMethylation450 BeadChip (HM450)].
Babalyan KA; Sultanov R; Generozov EV; Zakharzhevskaya NB; Sharova EI; Peshkov MN; Vasilev AO; Govorov AV; Pushkar DY; Prilepskaya EA; Danilenko SA; Babikova EA; Larin AK; Govorun VM
Vopr Onkol; 2016; 62(1):122-32. PubMed ID: 30444590
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
12. Can expressed prostatic secretions effect prostate biopsy decision of urologist?
Ergun O; Capar E; Goger YE; Ergun AG
Int Braz J Urol; 2019; 45(2):246-252. PubMed ID: 30648827
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of CD147 protein in prostate cancer].
He HC; Han ZD; Dai QS; Zou J; Zhang Y; Zhang Z; Liang YX; Ye YK; Chen ZN; Zhong WD
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1844-6. PubMed ID: 19953931
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers for prostate cancer.
Reynolds MA; Kastury K; Groskopf J; Schalken JA; Rittenhouse H
Cancer Lett; 2007 Apr; 249(1):5-13. PubMed ID: 17303324
[TBL] [Abstract][Full Text] [Related]
15. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
16. [Estimation of the diagnostic potential of APOD, PTOV1, and EPHA4 for prostatic neoplasms].
Allina DO; Andreeva YY; Zavalishina LE; Moskvina LV; Frank GA
Arkh Patol; 2016; 78(5):9-14. PubMed ID: 27804940
[TBL] [Abstract][Full Text] [Related]
17. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
19. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
Ghorbanmehr N; Gharbi S; Korsching E; Tavallaei M; Einollahi B; Mowla SJ
Prostate; 2019 Jan; 79(1):88-95. PubMed ID: 30194772
[TBL] [Abstract][Full Text] [Related]
20. [Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies].
Kovalev LI; Shishkin SS; Khasigov PZ; Dzeranov NK; Kazachenko AV; Toropygin IIu; Mamykina SV
Prikl Biokhim Mikrobiol; 2006; 42(4):480-4. PubMed ID: 17022460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
